IMCR
HEALTHCAREImmunocore Holdings Ltd
AI Insight
What's Moving IMCR Today?
No stock-specific AI insight has been generated for IMCR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$27.55$40.71
$29.99
Fundamentals
Market Cap$1.5B
P/E Ratio—
EPS$-0.56
Dividend Yield—
Dividend / Share—
ROE-7.1%
Profit Margin-6.7%
Debt / Equity—
Trading
Volume1.6M
Avg Volume (10D)—
Shares Outstanding50.9M
IMCR News
24 articles- RVMD Starts Treatment in Phase III Pancreatic Cancer Study on ZoldonrasibYahoo Finance·Jun 24, 2026
- GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASHYahoo Finance·Jun 24, 2026
- EU Clears SNY's Cenrifki for Secondary Progressive Multiple SclerosisYahoo Finance·Jun 23, 2026
- Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's WhyYahoo Finance·Jun 23, 2026
- Definium Stock Soars 50% as Phase III Depression Study Meets Key GoalsYahoo Finance·Jun 23, 2026
- Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS IIYahoo Finance·Jun 23, 2026
- QURE Announces Initial Data on Gene therapy for Temporal Lobe EpilepsyYahoo Finance·Jun 22, 2026
- Is Immunocore Holdings (IMCR) One of the Best Small Cap Stocks to Buy for the Long Term?Yahoo Finance·Jun 22, 2026
- QURE Soars as FDA Backs AMT-130 Data for Accelerated ApprovalYahoo Finance·Jun 19, 2026
- Immunocore Holdings (IMCR) Stock Could Be 57% Below Fair Value After Recent WeaknessYahoo Finance·Jun 19, 2026
- BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for PhenylketonuriaYahoo Finance·Jun 19, 2026
- Can Vertex's Kidney Pipeline Power Its Next Growth Phase?Yahoo Finance·Jun 19, 2026
- MRNA Up as Influenza Vaccine Wins Unanimous FDA Advisory Panel BackingYahoo Finance·Jun 19, 2026
- AGIO Stock Surges 35% in Six Months: What's Driving It?Yahoo Finance·Jun 18, 2026
- JAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor TherapiesYahoo Finance·Jun 18, 2026
- Corcept Resubmits NDA for Relacorilant in Cushing's SyndromeYahoo Finance·Jun 18, 2026
- MRNA Stock Jumps as FDA Briefing Docs Ease Flu Shot Approval ConcernsYahoo Finance·Jun 17, 2026
- DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?Yahoo Finance·Jun 17, 2026
- OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for ReviewYahoo Finance·Jun 17, 2026
- MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)Yahoo Finance·Jun 17, 2026
- 69,271 ADRs sale scheduled by Immunocore (NASDAQ: IMCR)Stock Titan·May 22, 2026
- How Investors May Respond To Immunocore (IMCR) Q1 Profitability and ESOP-Linked Share RegistrationSimply Wall Street·May 19, 2026
- Immunocore (IMCR) Is Up 9.7% After Strong Q1 Results And KIMMTRAK Survival Data ReleaseSimply Wall Street·May 11, 2026
- KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanomaGlobeNewswire Inc.·Apr 19, 2026
All 24 articles loaded
Price Data
Open$29.60
Previous Close$29.20
Day High$30.32
Day Low$29.60
52 Week High$40.71
52 Week Low$27.55
52-Week Range
$27.55$40.71
$29.99
Fundamentals
Market Cap$1.5B
P/E Ratio—
EPS$-0.56
Dividend Yield—
Dividend / Share—
ROE-7.1%
Profit Margin-6.7%
Debt / Equity—
Trading
Volume1.6M
Avg Volume (10D)—
Shares Outstanding50.9M
About Immunocore Holdings Ltd
Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases. The company is headquartered in Abingdon, the United Kingdom.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—